Value of post-vascular phase (Kupffer imaging) by contrast-enhanced ultrasonography using Sonazoid in the detection of hepatocellular carcinoma

Journal of Gastroenterology

Volumn 47, Issue 4, 2012, Pages 477-485

  Goto, Eriko ^a   Masuzaki, Ryota ^a   Tateishi, Ryosuke ^a   Kondo, Yuji ^a   Imamura, Jun ^a   Goto, Tadashi ^a   Ikeda, Hitoshi ^b   Akahane, Masaaki ^c   Shiina, Shuichiro ^a   Omata, Masao ^d   Yoshida, Haruhiko ^a   Koike, Kazuhiko ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOKYO HOSPITAL   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

^d Yamanashi Prefectural Hospital Organization   (Japan)

Author keywords

Contrast enhanced ultrasonography; Hepatocellular carcinoma; Sonazoid

Indexed keywords

PERFLUBUTANE;

ADULT; AGED; ARTICLE; B SCAN; CANCER PATIENT; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCED ULTRASONOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ERROR; DIAGNOSTIC IMAGING; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FEMALE; HOSPITAL ADMISSION; HUMAN; IMAGE ANALYSIS; INTERMETHOD COMPARISON; KUPFFER IMAGING; LIVER CELL CARCINOMA; LIVER CYST; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY AND SPECIFICITY; SIGNAL DETECTION; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; CONTRAST MEDIA; FEMALE; FERRIC COMPOUNDS; HUMANS; IMAGE ENHANCEMENT; IRON; LIVER; LIVER NEOPLASMS; MALE; MIDDLE AGED; OXIDES; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED; ULTRASONOGRAPHY;

EID: 84863102376     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-011-0512-9     Document Type: Article

References (30)

1. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003;362(9399):1907-17. (Pubitemid 37518510)
2. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55(2):74-108. (Pubitemid 40372904)
3. El-Serag HB. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology. 2004;127(5 Suppl 1):S27-34. (Pubitemid 39423367)
4. Colombo M, de Franchis R, Del Ninno E, Sangiovanni A, De Fazio C, Tommasini M, et al. Hepatocellular carcinoma in Italian patients with cirrhosis. N Engl J Med. 1991;325(10):675-80.
5. Makuuchi M, Kokudo N. Clinical practice guidelines for hepatocellular carcinoma: the first evidence based guidelines from Japan. World J Gastroenterol. 2006;12(5):828-9. (Pubitemid 43380776)
6. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al. Clinical management of hepatocellular carcinoma. Conclusions: of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol. 2001;35(3):421-30. (Pubitemid 32844200)
7. Yanagisawa K, Moriyasu F, Miyahara T, Yuki M, Iijima H. Phagocytosis of ultrasound contrast agent microbubbles by Kupffer cells. Ultrasound Med Biol. 2007;33(2):318-25. (Pubitemid 46240604)
8. Tanaka M, Nakashima O, Wada Y, Kage M, Kojiro M. Pathomorphological study of Kupffer cells in hepatocellular carcinoma and hyperplastic nodular lesions in the liver. Hepatology. 1996; 24(4):807-12. (Pubitemid 26334277)
9. Shunichi S, Hiroko I, Fuminori M, Waki H. Definition of contrast enhancement phases of the liver using a perfluoro-based microbubble agent, perflubutane microbubbles. Ultrasound Med Biol. 2009;35(11):1819-27.
10. Kindberg GM, Tolleshaug H, Roos N, Skotland T. Hepatic clearance of Sonazoid perfluorobutane microbubbles by Kupffer cells does not reduce the ability of liver to phagocytose or degrade albumin microspheres. Cell Tissue Res. 2003;312(1):49-54. (Pubitemid 36578845)
11. Hatanaka K, Kudo M, Minami Y, Maekawa K. Sonazoid-enhanced ultrasonography for diagnosisofhepatic malignancies: comparison with contrast-enhanced CT. Oncology. 2008;75(Suppl 1):42-7.
12. Moriyasu F, Itoh K. Efficacy of perflubutane microbubbleenhanced ultrasound in the characterization and detection of focal liver lesions: phase 3 multicenter clinical trial. AJR Am J Roentgenol. 2009;193(1):86-95.
13. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, et al. The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration. Ann Intern Med. 2003;138(1):W1-12.
14. The committee for revision of the clinical practice guidelines for hepatocellular carcinoma. Clinical practice guidelines for hepatocellular carcinoma - The Japan Society of Hepatology 2009 update. Hepatol Res. 2010;40(s1):16-47 (Practice Guideline).
15. Youden WJ. Index for rating diagnostic tests. Cancer. 1950;3(1): 32-5.
16. Thompson Coon J, Rogers G, Hewson P, Wright D, Anderson R, Cramp M, et al. Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis. Health Technol Assess. 2007;11(34):1-206.
17. Watanabe R, Matsumura M, Munemasa T, Fujimaki M, Suematsu M. Mechanism of hepatic parenchyma-specific contrast of microbubble-based contrast agent for ultrasonography: microscopic studies in rat liver. Invest Radiol. 2007;42(9):643-51. (Pubitemid 47262933)
18. Saini S, Stark DD, Hahn PF, Bousquet JC, Introcasso J, Wittenberg J, et al. Ferrite particles: a superparamagnetic MR contrast agent for enhanced detection of liver carcinoma. Radiology. 1987;162(1 Pt 1):217-22. (Pubitemid 17001813)
19. Stark DD, Weissleder R, Elizondo G, Hahn PF, Saini S, Todd LE, et al. Superparamagnetic iron oxide: clinical application as a contrast agent for MR imaging of the liver. Radiology. 1988; 168(2):297-301.
20. Asahina Y, Izumi N, Uchihara M, Noguchi O, Ueda K, Inoue K, et al. Assessment of Kupffer cells by ferumoxides-enhanced MR imaging is beneficial for diagnosis of hepatocellular carcinoma: comparison of pathological diagnosis and perfusion patterns assessed by CT hepatic arteriography and CT arterioportography. Hepatol Res. 2003;27(3):196-204. (Pubitemid 37407667)
21. Imai Y, Murakami T, Yoshida S, Nishikawa M, Ohsawa M, Tokunaga K, et al. Superparamagnetic iron oxide-enhanced magnetic resonance images of hepatocellular carcinoma: correlation with histological grading. Hepatology. 2000;32(2):205-12. (Pubitemid 30614651)
22. Blomley MJ, Albrecht T, Cosgrove DO, Patel N, Jayaram V, Butler-Barnes J, et al. Improved imaging of liver metastases with stimulated acoustic emission in the late phase of enhancement with the US contrast agent SH U 508A: early experience. Radiology. 1999;210(2):409-16. (Pubitemid 29055309)
23. Numata K, Morimoto M, Ogura T, Sugimori K, Takebayashi S, Okada M, et al. Ablation therapy guided by contrast-enhanced sonography with Sonazoid for hepatocellular carcinoma lesions not detected by conventional sonography. J Ultrasound Med. 2008;27(3):395-406. (Pubitemid 351428123)
24. Luo W, Numata K, Morimoto M, Kondo M, Takebayashi S, Okada M, et al. Focal liver tumors: characterization with 3D perflubutane microbubble contrast agent-enhanced US versus 3D contrastenhanced multidetector CT. Radiology. 2009;251(1):287-95.
25. Kudo M. New sonographic techniques for the diagnosis and treatment of hepatocellular carcinoma. Hepatol Res. 2007; 37(Suppl 2):S193-9.
26. Hohmann J, Albrecht T, Hoffmann CW, Wolf KJ. Ultrasonographic detection of focal liver lesions: increased sensitivity and specificity with microbubble contrast agents. Eur J Radiol. 2003;46(2):147-59. (Pubitemid 36457936)
27. Hirokawa Y, Isoda H, Maetani YS, Arizono S, Shimada K, Okada T, et al. Hepatic lesions: improved image quality and detection with the periodically rotated overlapping parallel lines with enhanced reconstruction technique - evaluation of SPIO-enhanced T2-weighted MR images. Radiology. 2009;251(2): 388-97.
28. Vogl TJ, Schwarz W, Blume S, Pietsch M, Shamsi K, Franz M, et al. Preoperative evaluation of malignant liver tumors: comparison of unenhanced and SPIO (Resovist)-enhanced MR imaging with biphasic CTAP and intraoperative US. Eur Radiol. 2003;13(2):262-72. (Pubitemid 36798602)
29. Edey AJ, Ryan SM, Beese RC, Gordon P, Sidhu PS. Ultrasound imaging of liver metastases in the delayed parenchymal phase following administration of Sonazoid using a destructive mode technique (Agent Detection Imaging). Clin Radiol. 2008;63(10): 1112-20.
30. Kudo M. Will Gd-EOB-MRI change the diagnostic algorithm in hepatocellular carcinoma? Oncology. 2010;78(Suppl 1):87-93.